Sol-Gel Technologies Ltd. (SLGL) is an Israel-based specialty pharmaceutical company with a primary focus on dermatology. The company has established itself as a pioneer in the field of topical dermatological drug delivery, aiming to improve people's lives with its innovative products. Sol-Gel Technologies is publicly traded on the Nasdaq exchange under the ticker symbol 'SLGL'.
Founded in 1997, Sol-Gel has built its reputation as a proficient developer of unique drug delivery systems, leveraging its proprietary technology to enhance the delivery, efficiency, and safety of existing therapies. Its proprietary platform is based on silica-based encapsulation technology, which entraps active ingredients in a protective shield of silica, allowing for controlled drug release and improved stability. This approach has given the company a competitive edge in the field of dermatology treatments.
Sol-Gel Technologies has a diverse drug portfolio, with drugs targeting acne, rosacea, and other dermatological conditions. Its pipeline includes two FDA-approved drugs, Epsolay® for rosacea and Twyneo® for acne, which was approved in 2021. The company is actively seeking commercialization partnerships for these products.
The company’s core strategy is to leverage its proprietary drug delivery system to enhance or reformulate existing drugs, reducing development risk and time. A significant advantage of this strategy is the potential to reduce side effects while improving efficacy, as the drug delivery system allows for a lower dosage of the active ingredient to be administered without compromising results.
While Sol-Gel Technologies has accomplished major successes in the development of dermatological treatments, the company is persistent in its research and development efforts to address other clinical needs in dermatology and beyond. It's this committed, innovative approach that has made Sol-Gel Technologies a trusted leader in the dermatology pharmaceutical space.
Investors view Sol-Gel Technologies as a promising player in the pharmaceutical industry, not only because of its technological prowess but also because of its impressive track record of achieving regulatory approvals. The company’s commitment to robust research and development, coupled with its strategic alliances with commercialization partners, positions it for consistent growth.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sol-Gel Technologies announced the completion of the last patient last visit in its pivotal Phase 3 clinical trial for SGT-610, an investigational treatment for Gorlin syndrome. This milestone signifies the end of the patient treatment and follow-up phase, with top-line results expected in late November 2026. SGT-610 aims to prevent basal cell carcinoma lesions in Gorlin syndrome patients, addressing a significant unmet medical need.
Sol-Gel Technologies announced the completion of the last patient's last visit in its pivotal Phase 3 clinical trial for SGT-610 (patidegib gel, 2%), aimed at preventing basal cell carcinoma lesions in adult Gorlin syndrome patients. The company has now concluded the patient treatment and follow-up phase and will proceed with database lock and statistical analysis. Top-line results are anticipated in late November 2026.
Sol-Gel Technologies (SLGL) has recently formed a 'hammer chart pattern' after an 8.3% stock loss, indicating a potential trend reversal due to exhausted selling pressure and emerging buying interest. This technical signal is supported by strong fundamental factors, including a 33.4% increase in consensus EPS estimates for the current year and a Zacks Rank #2 (Buy), suggesting outperformance potential. Investors are advised to consider SLGL for "bottom fishing" given these combined bullish indicators.
Opaleye Management, a 10% stakeholder in Sol-Gel Technologies (NASDAQ: SLGL), acquired 9,976 shares through five separate transactions between September 4 and September 9, 2026. The share prices ranged from $68.70 to $69.52. These purchases increase Opaleye's total holdings to 536,876 shares, reflecting their continued investment in the company.
Sol-Gel Technologies (SLGL) is awaiting crucial Phase 3 results for SGT-610, its treatment for Gorlin syndrome, expected in late November 2026. The Israeli dermatology company's portfolio includes approved treatments like Epsolay and Twyneo, and a pipeline featuring SGT-610 and SGT-210. The full article content is exclusive to RTT Biotech Investor and Intelligent Investor subscribers.
Sol-Gel Technologies Ltd. reported a significant financial downturn in Q2 2026, with a loss of $1.13 per share and a net loss of $3.7 million, a sharp reversal from earnings in the prior year. Revenue plummeted by 96.6% due to reduced commercial income as the company invests heavily in its clinical pipeline for dermatological treatments. Despite the setback, analysts maintain a generally positive outlook with seven buy ratings.
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly earnings, significantly beating analyst expectations with a loss of $1.13 per share against an estimated loss of $2.36, and revenue of $0.59 million against a $0.07 million forecast. Despite continued unprofitability and stock volatility, analyst sentiment remains a "Moderate Buy" with an average price target of $197.50, and insiders have increased their holdings.
Sol-Gel Technologies announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates. The company's pivotal Phase 3 clinical trial for SGT-610 in Gorlin syndrome is progressing, with top-line results expected in late November 2026, and patient dropout rates are lower than anticipated. Sol-Gel also initiated new studies for patidegib gel in high-frequency basal cell carcinoma and as a neo-adjuvant in BCC surgery, while filing a provisional patent for an intra-cystic injectable treatment for odontogenic keratocysts, expanding the potential applications of its hedgehog inhibitor expertise.